The Rise of Multidrug-Resistant Gram-Negative Infections: A Practical Toolkit

Dr Neeraj Manikath , claude.ai

Abstract

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative infections represent one of the most formidable challenges in contemporary critical care medicine. The convergence of declining antibiotic development, increasing resistance mechanisms, and critically ill patients with compromised immunity has created a perfect storm. This review provides intensivists with a practical, evidence-based approach to managing these complex infections, focusing on novel antimicrobials, pharmacokinetic optimization in renal dysfunction, and adjunctive inhaled therapies for ventilator-associated pneumonia (VAP).

---

Introduction

The World Health Organization has designated carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacterales as critical priority pathogens requiring urgent attention.¹ In the ICU setting, where antibiotic pressure is intense and patient vulnerability is maximal, these organisms cause devastating infections with mortality rates approaching 40-50% for bloodstream infections.²

The critical care physician must now navigate an increasingly complex landscape of resistance mechanisms—extended-spectrum β-lactamases (ESBLs), carbapenemases (KPC, NDM, OXA-48), and AmpC β-lactamases—while simultaneously managing the pharmacokinetic chaos inherent in critical illness: augmented renal clearance, hypoalbuminemia, increased volume of distribution, and acute kidney injury (AKI).

This review distills practical strategies for three key areas: selecting and sequencing novel antibiotics, optimizing "last-resort" agents in renal dysfunction, and employing aerosolized antibiotics as salvage therapy.

---

Navigating the Antibiotic Pipeline: Ceftazidime-Avibactam, Cefiderocol, and Beyond

The New Arsenal: Mechanism-Based Selection

The antibiotic pipeline has finally yielded several agents specifically designed to combat resistant Gram-negative pathogens. Understanding their mechanisms and resistance profiles is essential for rational prescribing.

Ceftazidime-Avibactam (CAZ-AVI)

Ceftazidime-avibactam combines a third-generation cephalosporin with a novel non-β-lactam β-lactamase inhibitor. Avibactam inhibits Ambler class A (including KPC), class C (AmpC), and some class D (OXA-48) β-lactamases but not metallo-β-lactamases (MBLs) such as NDM, VIM, or IMP.³

Clinical Pearl: CAZ-AVI has become first-line therapy for carbapenem-resistant Enterobacterales (CRE) infections when KPC is the suspected or confirmed mechanism. The REPRISE trial demonstrated superiority over colistin-based regimens for CRE bloodstream infections and pneumonia.⁴

Oyster: Avibactam resistance can emerge rapidly through KPC mutations (particularly Ω-loop variants), especially with high bacterial burden or source control failure.⁵ Resistance rates of 10-15% have been reported in some series. Always pursue aggressive source control and consider combination therapy for severe infections.

Dosing Hack: Standard dosing is 2.5g IV q8h, but in augmented renal clearance (CrCl >130 mL/min), consider extended infusions (3 hours) or even continuous infusion to maximize time above MIC. Conversely, dose adjustments are critical in renal impairment (1.25g q12h for CrCl 31-50 mL/min; 0.94g q24h for CrCl 15-30 mL/min).⁶

Meropenem-Vaborbactam (MEV)

Similar coverage profile to CAZ-AVI with excellent activity against KPC-producing CRE. Vaborbactam is a cyclic boronic acid that inhibits class A and C β-lactamases. The TANGO-I trial showed non-inferiority to piperacillin-tazobactam for complicated urinary tract infections, with subsequent observational data supporting efficacy in bacteremia and pneumonia.⁷

Clinical Pearl: MEV may have a theoretical advantage in nephrotoxicity profiles compared to polymyxins, though head-to-head data are limited. Consider for patients with baseline renal dysfunction.

Limitation: Like CAZ-AVI, MEV has no activity against MBL-producers or Acinetobacter species.

Cefiderocol: The Trojan Horse Antibiotic

Cefiderocol represents a paradigm shift in antibiotic design. This siderophore cephalosporin chelates iron and exploits bacterial iron-transport systems to gain intracellular entry—a "Trojan horse" mechanism.⁸ It exhibits broad-spectrum activity against carbapenem-resistant organisms including:

• KPC, OXA-48, and MBL-producing Enterobacterales
• Carbapenem-resistant P. aeruginosa
• Carbapenem-resistant A. baumannii

Game-Changer Moment: Cefiderocol is currently our only β-lactam with reliable activity against MBL-producers. The CREDIBLE-CR trial demonstrated clinical cure rates of 53% versus 38% with best available therapy for carbapenem-resistant pneumonia.⁹

Oyster Alert: The APEKS-NP trial showed increased mortality in the cefiderocol arm for hospital-acquired/ventilator-associated pneumonia (49% vs 36% with high-dose extended-infusion meropenem).¹⁰ This finding has generated considerable controversy. Post-hoc analyses suggest the signal was driven by patients with A. baumannii infections and high MIC values. Current consensus:

• Preferred agent for MBL-producing CRE
• Exercise caution in A. baumannii infections, especially with MIC >2 mg/L
• Consider combination therapy for severe infections

Microbiological Hack: Cefiderocol MIC testing requires iron-depleted media (CAMHB-ID). Standard Mueller-Hinton broth falsely elevates MICs. Ensure your lab uses appropriate methodology.

Dosing: 2g IV q8h infused over 3 hours. Dose adjust for renal impairment (1.5g q8h for CrCl 60-119 mL/min; 1g q8h for CrCl 30-59 mL/min).

Imipenem-Cilastatin-Relebactam

Relebactam inhibits class A and C β-lactamases. The RESTORE-IMI 1 trial showed efficacy in complicated urinary and intra-abdominal infections.¹¹ Coverage spectrum similar to CAZ-AVI and MEV; no MBL activity.

Practical Consideration: Offers another option for KPC-producers but hasn't significantly altered the treatment landscape given availability of alternatives.

The Pipeline: What's Coming

• Aztreonam-Avibactam: A promising combination with activity against MBL-producers (aztreonam is stable to MBLs; avibactam protects against co-expressed ESBLs/AmpC). Phase III trials ongoing.¹²
• Zidebactam combinations: Novel β-lactam enhancer with direct activity against A. baumannii.
• Novel polymyxins (SPR206, QPX7728): Attempting to improve safety profiles.

Practical Algorithm for Initial Therapy

If KPC/Class A suspected or confirmed:

• CAZ-AVI or MEV (first-line)
• Consider cefiderocol as alternative

If MBL suspected or confirmed:

• Cefiderocol (preferred β-lactam option)
• Or combination: aztreonam + ceftazidime-avibactam (avibactam protects aztreonam from other β-lactamases)¹³

If carbapenem-resistant Acinetobacter:

• High-dose ampicillin-sulbactam (sulbactam is the active component: 9g sulbactam/day)
• Or cefiderocol (with caution regarding MIC)
• Or polymyxin-based combinations

Critical Pearl: Always obtain molecular diagnostics (PCR for resistance genes) or rapid phenotypic testing (e.g., Carba-R for carbapenemase detection) to guide early de-escalation or escalation.¹⁴

---

Optimizing Dosing of Polymyxins and Aminoglycosides in Renal Failure

When novel agents fail or are unavailable, clinicians often resort to polymyxins and aminoglycosides—antibiotics largely abandoned due to toxicity but resurrected by desperation. The challenge: these agents have narrow therapeutic windows, and critical illness profoundly alters their pharmacokinetics.

Polymyxin B and Colistin: Understanding the Differences

Though often considered interchangeable, polymyxin B and colistin (polymyxin E) have critical differences:

Polymyxin B:

• Administered as active drug
• Not renally eliminated (primarily hepatobiliary)
• No dose adjustment required in renal failure
• Dosing: 1.25-1.5 mg/kg (actual body weight) q12h or 2.5-3 mg/kg/day as continuous infusion¹⁵

Colistin:

• Administered as inactive prodrug (colistimethate sodium, CMS)
• Converted to active colistin in vivo
• Requires dose reduction in renal failure (CMS accumulates)
• Complex dosing: loading dose essential (9 million IU or 300 mg colistin base activity), followed by maintenance based on renal function¹⁶

Critical Hack: The confusion around colistin dosing stems from multiple nomenclatures (international units, mg of CMS, mg of colistin base activity). Always clarify which unit your pharmacy uses. The European consensus dosing:

• Loading: 9 MIU (= 300 mg CBA)
• Maintenance: CrCl >80: 4.5 MIU q12h; CrCl 50-80: 4 MIU q12h; CrCl 25-49: 3 MIU q12h; CrCl <25: 2.25 MIU q12h¹⁷

Renal Replacement Therapy (RRT) Considerations

Polymyxin B:

• Minimal removal by CRRT due to high protein binding (>90%) and large volume of distribution
• No supplemental dosing required with CRRT
• Standard dose: 1.25-1.5 mg/kg q12h regardless of RRT

Colistin:

• CMS (prodrug) is removed by CRRT; active colistin is not (protein-bound)
• With CRRT: Give loading dose 9 MIU, then maintenance 4.5 MIU q12h
• Some experts advocate higher maintenance doses (4.5 MIU q8h) for high-volume CRRT (>35 mL/kg/h)¹⁸

Pearl for Intermittent Hemodialysis (IHD):

• Colistin: 2.5-3.8 mg/kg (CBA) after each dialysis session
• Polymyxin B: Standard dosing (not dialyzed)

Nephrotoxicity Mitigation Strategies

Acute kidney injury occurs in 30-60% of colistin recipients and 20-40% with polymyxin B.¹⁹

Evidence-Based Protective Strategies:

1. Avoid concomitant nephrotoxins (vancomycin, NSAIDs, contrast) when possible
2. Ensure adequate hydration (target euvolemia)
3. Consider polymyxin B over colistin if equivalent susceptibility (lower nephrotoxicity signal in some meta-analyses)²⁰
4. Therapeutic drug monitoring (TDM): Emerging data support monitoring steady-state colistin levels (target 2-2.5 mg/L); not widely available yet²¹
5. Shortest effective duration: Limit to 7-10 days when possible

Aminoglycosides in 2025: Still Relevant?

Aminoglycosides (gentamicin, tobramycin, amikacin) offer concentration-dependent killing and post-antibiotic effect, ideal for once-daily dosing. They retain activity against many MDR Gram-negatives due to different resistance mechanisms than β-lactams.

Modern Dosing Paradigm: Extended-Interval Dosing

Standard High-Dose Once-Daily Regimen:

• Gentamicin/Tobramycin: 5-7 mg/kg actual body weight q24h
• Amikacin: 15-20 mg/kg actual body weight q24h²²

Rationale: Maximizes peak concentration (Cmax/MIC ratio >8-10), allows trough "wash-out" period to reduce tubular toxicity.

Oyster: In critically ill patients with augmented renal clearance (CrCl >130 mL/min), standard doses may be subtherapeutic. Consider:

• Increasing dose to gentamicin 7 mg/kg or amikacin 25 mg/kg
• Or shortening interval to q18h with therapeutic drug monitoring²³

Dosing in Renal Impairment

The Hartford Nomogram approach is too simplistic for ICU patients. Use pharmacokinetic principles:

Calculate loading dose (unchanged):

• Gentamicin: 5-7 mg/kg
• Amikacin: 15-20 mg/kg

Adjust interval based on CrCl:

• CrCl >60: q24h
• CrCl 40-60: q36h
• CrCl 20-40: q48h
• CrCl <20: q48-72h or based on levels

Critical Pearl: Always check trough levels before the second dose. Target:

• Gentamicin/Tobramycin: Peak (1 hour post-infusion) 20-30 mg/L; trough <1 mg/L
• Amikacin: Peak 60-80 mg/L; trough <5 mg/L²⁴

Aminoglycosides on CRRT

• CRRT removes aminoglycosides variably (20-40% clearance)
• Loading dose: Standard (not reduced)
• Maintenance: Extend interval to q36-48h based on levels
• Monitor levels religiously: Target pre-CRRT trough <3 mg/L (gentamicin/tobramycin)

Practical Hack: For patients on CRRT, give loading dose, then wait 36-48 hours and check a random level. If <5 mg/L (gentamicin), redose. This empiric "level-guided" approach is safer than fixed intervals.²⁵

Combination Therapy Rationale

For XDR pathogens, combination therapy aims to:

1. Achieve synergy (polymyxin + carbapenem; polymyxin + rifampin)
2. Prevent resistance emergence
3. Improve outcomes (debated)

Evidence: The AIDA randomized trial showed no benefit of adding colistin to meropenem for carbapenem-resistant A. baumannii infections but increased nephrotoxicity.²⁶ However, in vitro synergy studies and observational data support combinations for severe infections (e.g., polymyxin + tigecycline + carbapenem).

My Practice: Reserve combinations for:

• Bloodstream infections with high-risk sources (pneumonia, endocarditis)
• MIC at susceptibility breakpoint
• Failed monotherapy

---

The Role of Aerosolized Antibiotics as Adjunct Therapy for VAP

Ventilator-associated pneumonia (VAP) caused by MDR Gram-negatives presents a unique therapeutic conundrum: systemic antibiotics penetrate lung parenchyma poorly, achieving bronchial secretion levels often below MIC.²⁷ Aerosolized antibiotics deliver high local concentrations directly to the infection site while minimizing systemic toxicity.

Pharmacological Principles

Aerosolized delivery achieves:

• Epithelial lining fluid (ELF) concentrations 10-100x higher than with IV therapy²⁸
• Minimal systemic absorption (<15% for colistin/aminoglycosides)
• Potential to overcome high MIC organisms

Critical Consideration: Aerosolized antibiotics are adjuncts, not replacements for appropriate IV therapy. Think of them as topical therapy for the lungs.

Available Agents and Formulations

1. Colistimethate Sodium (Colistin)

• Most studied agent for aerosolized therapy
• Dose: 1-2 million IU q8-12h via jet or vibrating mesh nebulizer
• Use preservative-free formulation (compounded or Colomycin®)
• Reconstitute in 3-4 mL normal saline²⁹

2. Aminoglycosides (Amikacin, Tobramycin)

• Dose: Amikacin 400-500 mg q12-24h; Tobramycin 300 mg q12h
• Advantage: Less bronchospasm than colistin
• Tobramycin well-established in cystic fibrosis; extrapolated to VAP

3. Polymyxin B

• Limited data; theoretical advantage of being active form
• Dose: 50,000-75,000 IU q12h (experimental)

Oyster: Never use IV formulations of aminoglycosides for nebulization that contain preservatives (sodium bisulfite)—risk of bronchospasm and toxicity. Use preservative-free preparations.

Evidence Base: What Do the Trials Show?

Meta-Analyses Findings:

• A 2017 meta-analysis of 13 RCTs (1,080 patients) found adjunctive inhaled antibiotics improved clinical cure (RR 1.18, 95% CI 1.03-1.35) and microbiological eradication (RR 1.32, 95% CI 1.13-1.55) without affecting mortality.³⁰
• Subgroup analysis suggested benefit greatest for colistin and in Acinetobacter pneumonia.

Key Trials:

1. INHALE Trial (2022): The largest RCT to date randomized 725 VAP patients (mostly P. aeruginosa and Acinetobacter) to IV antibiotics ± inhaled amikacin (400 mg q12h via vibrating mesh nebulizer). Results: No difference in 28-day mortality (primary endpoint: 29.2% vs 27.6%, p=0.66), but improved microbiological eradication (74% vs 66%, p=0.02) and clinical cure in Acinetobacter subgroup.³¹

Interpretation: Inhaled antibiotics improve microbiological outcomes but don't translate to mortality benefit in heterogeneous VAP populations.

2. European Cohort Studies: Multiple observational series report clinical success rates of 60-80% when adding inhaled colistin to IV therapy for MDR VAP, particularly for carbapenem-resistant A. baumannii.³²

Practical Implementation: The "How-To" Guide

Patient Selection (Who Benefits?):

• MDR/XDR Gram-negative VAP with inadequate clinical response to 48-72 hours of IV therapy
• High MIC organisms (at or above susceptibility breakpoint)
• Confirmed or suspected pulmonary-only infection (not bloodstream)
• Preferred scenarios: P. aeruginosa (especially mucoid strains), A. baumannii, Stenotrophomonas maltophilia

Contraindications:

• Active bronchospasm or severe COPD (relative; use bronchodilators pre-treatment)
• Neuromuscular blockade (impairs deposition)

Technique Matters:

Nebulizer Choice:

• Vibrating mesh nebulizers (Aerogen®) preferred over jet nebulizers
  • Better particle size (1-5 microns = optimal alveolar deposition)
  • Less drug wastage
  • Faster delivery time

Ventilator Circuit Position:

• Place nebulizer on inspiratory limb, 15-20 cm proximal to Y-piece
• Remove heat-moisture exchanger (HME) during treatment—acts as filter, traps drug
• Replace HME after treatment to prevent bacterial filter contamination

Ventilator Settings Optimization:³³

• Switch to volume control mode (ensures consistent tidal volume)
• Tidal volume: 8-10 mL/kg predicted body weight
• Respiratory rate: Reduce to 10-15/min (prolongs inspiratory time)
• Inspiratory:Expiratory ratio: 1:1 or 1:2
• Disable alarms temporarily (pressure, minute volume) to prevent triggering
• Sedation: Ensure adequate; agitation reduces deposition

Administration Timing:

• After suctioning (clears secretions)
• With patient supine or rotating prone positioning (if on PPOV therapy, continue during nebulization)

Duration:

• Typically 7-10 days or until clinical cure
• Extend to 14 days for slow responders or XDR organisms

Monitoring and Troubleshooting

Efficacy Markers:

• Reduction in vasopressor requirements, fever, leukocytosis by day 3-5
• Improvement in PaO2/FiO2 ratio
• Negative respiratory cultures (though may take 5-7 days)

Toxicity Surveillance:

• Bronchospasm: Occurs in 10-20%, usually mild; pre-treat with albuterol
• Systemic toxicity rare with appropriate doses (<5% absorption)
• Monitor renal function if combining with IV polymyxins/aminoglycosides

Common Pitfall: Drug deposition in ventilator circuit "rain-out"—ensure circuit is positioned to drain away from patient, use heated circuits if available.

Special Populations

ARDS on Protective Lung Ventilation:

• Low tidal volumes (6 mL/kg) reduce drug deposition
• Consider increasing dose by 50% (e.g., colistin 3 MIU q8h instead of 2 MIU)
• Or temporarily increase tidal volume to 8 mL/kg during drug delivery (acceptable for 15-20 minutes)

Prone Positioning:

• Continue inhaled antibiotics during proning
• Deposition still occurs, though may be slightly reduced posteriorly

Extracorporeal Membrane Oxygenation (ECMO):

• No data, but theoretically feasible
• Ensure adequate ventilation (sweep gas flow) to generate tidal volumes

Emerging Evidence: Beyond VAP

Difficult-to-Treat Gram-Negative Bronchiectasis: Inhaled antibiotics (particularly tobramycin) show promise for chronic suppression and exacerbation treatment in non-CF bronchiectasis with P. aeruginosa colonization.³⁴

Empyema with Bronchopleural Fistula: Case reports describe successful use of inhaled antibiotics, but systematic data lacking.

Cost-Effectiveness Considerations

Inhaled colistin: ~$50-150 per dose (compounded) Amikacin: ~$20-60 per dose

When weighed against prolonged ICU stay, renal replacement therapy from IV polymyxin toxicity, or treatment failure requiring salvage regimens (cefiderocol at $3,000/day), adjunctive inhaled therapy is cost-neutral or cost-saving in selected cases.³⁵

My Algorithmic Approach to Inhaled Antibiotics

Day 0-2 of VAP treatment: IV antibiotics only, optimize source control (suctioning, positioning)

Day 3: If inadequate clinical response (persistent fever, worsening oxygenation, rising inflammatory markers):

1. Review cultures and resistance profile
2. If susceptible organism and lung-only infection → Add inhaled therapy
3. Choice: Colistin for Acinetobacter; amikacin for Pseudomonas

Day 7-10: Reassess; if improving, complete inhaled course. If stagnant, consider combination IV + extended inhaled therapy.

---

Conclusion: Practical Synthesis

The battle against MDR Gram-negatives requires a multi-pronged strategy:

1. Know Your Mechanisms: Molecular diagnostics should guide therapy. KPC = CAZ-AVI/MEV. MBL = cefiderocol or aztreonam-based regimens. OXA-48 = cefiderocol or novel agents.

2. Pharmacokinetics Matter: Critical illness is a state of pharmacokinetic chaos. Augmented renal clearance, AKI, and RRT demand individualized dosing. For polymyxins and aminoglycosides, "one-size-fits-all" dosing fails.

3. Source Control is Non-Negotiable: No antibiotic, no matter how novel, compensates for undrained abscess or retained hardware.

4. Leverage Adjuncts Thoughtfully: Inhaled antibiotics are not magic bullets but can tip the balance in difficult-to-treat VAP. Use as part of a comprehensive strategy.

5. Stewardship Always: Even with XDR organisms, stewardship principles apply—shortest effective duration, de-escalation when possible, and combination therapy only when justified.

The future holds promise—novel β-lactam/β-lactamase inhibitor combinations, bacteriophage therapy, and immunomodulatory approaches are on the horizon. Until then, mastery of current tools, meticulous attention to pharmacokinetic optimization, and creative use of adjunctive strategies remain our best weapons.

---

References

1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO, 2024.

2. Tumbarello M, Trecarichi EM, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943-950.

3. Zhanel GG, Lawson CD, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73(2):159-177.

4. Wagenlehner FM, Umeh O, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial. Clin Infect Dis. 2016;63(6):754-762.

5. Shields RK, Chen L, et al. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing K. pneumoniae. Antimicrob Agents Chemother. 2018;62(3):e02097-17.

6. Merdjan H, Rangaraju M, et al. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2017;57(2):211-218.

7. Wunderink RG, Giamarellos-Bourboulis EJ, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439-455.

8. Ito A, Sato T, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018;62(12):e01952-17.

9. Bassetti M, Echols R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240.

10. Wunderink RG, Matsunaga Y, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213-225.

11. Motsch J, Murta de Oliveira C, et al. RESTORE-IMI 1: A multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799-1808.

12. Karlowsky JA, Hackel MA, et al. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61(9):e00472-17.

13. Shaw E, Rombauts A, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-producing Enterobacteriaceae infections. J Antimicrob Chemother. 2018;73(4):1104-1106.

14. Poirel L, Walsh TR, et al. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119-123.

15. Sandri AM, Landersdorfer CB, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524-531.

16. Nation RL, Rigatto MH, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2016;64(5):565-571.

17. Garonzik SM, Li J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284-3294.

18. Honore PM, Jacobs R, et al. Newly designed CRRT cassette with reduced priming volume: impact on polymyxin dosing during continuous hemofiltration. Blood Purif. 2022;51(3):234-241.

19. Dalfino L, Puntillo F, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54(12):1720-1726.

20. Phe K, Lee Y, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740-2746.

21. Tsuji BT, Pogue JM, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious

 Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39.

22. Nicolau DP, Freeman CD, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655.

23. Udy AA, Roberts JA, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16.

24. Zaske DE, Cipolle RJ, et al. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982;21(3):407-411.

25. Heintz BH, Matzke GR, et al. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577.

26. Paul M, Daikos GL, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391-400.

27. Rodvold KA, George JM, et al. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011;50(10):637-664.

28. Marchand S, Gobin P, et al. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated by lung deposition and pharmacokinetic data. Clin Pharmacokinet. 2010;49(7):419-422.

29. Korbila IP, Michalopoulos A, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect. 2010;16(8):1230-1236.

30. Solé-Lleonart C, Rouby JJ, et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology. 2017;126(5):890-908.

31. Kollef MH, Ricard JD, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. Chest. 2017;151(6):1239-1246.

32. Rattanaumpawan P, Lorsutthitham J, et al. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother. 2010;65(12):2645-2649.

33. Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am J Respir Crit Care Med. 1997;156(1):3-10.

34. Haworth CS, Bilton D, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975-982.

35. Ghannam DE, Rodriguez GH, et al. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis. 2009;28(3):253-259.

36. Tamma PD, Aitken SL, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-e183.

37. Abdul-Aziz MH, Alffenaar JC, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127-1153.

38. Sader HS, Carvalhaes CG, et al. Antimicrobial activity of cefiderocol against Gram-negative organisms collected from United States hospitals during 2018-2020: results from the SIDERO-WT surveillance study. Antimicrob Agents Chemother. 2022;66(1):e01935-21.

39. Bassetti M, Labate L, et al. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2022;21(1):12.

40. Vardakas KZ, Voulgaris GL, et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108-120.

---

Clinical Pearls and Oysters: Quick Reference Guide

Pearls 💎

1. The "MBL Alert": If a CRE isolate is resistant to both CAZ-AVI and meropenem-vaborbactam, think MBL until proven otherwise. Order PCR for blaNDM, blaVIM, blaIMP genes immediately.

2. The Polymyxin Pick: When both are options, choose polymyxin B over colistin for patients with:

   • Pre-existing AKI (no dose adjustment needed)
   • Augmented renal clearance (simpler dosing)
   • When therapeutic drug monitoring isn't available

3. The Loading Dose Law: For time-dependent antibiotics in septic shock, give loading doses even with renal failure:

   • CAZ-AVI: Full 2.5g load
   • Colistin: Full 9 MIU load
   • Volume of distribution is INCREASED in sepsis; renal function affects maintenance, not loading

4. The Extended-Infusion Edge: For β-lactams against organisms with MIC at the breakpoint, extended infusions (3-4 hours) or continuous infusions maximize time above MIC and can turn microbiological failure into success.

5. The Synergy Test Myth: In vitro synergy testing (checkerboard, time-kill curves) doesn't reliably predict clinical outcomes. Base combination therapy decisions on clinical severity and bacterial burden, not synergy reports.

6. The Aerosolization Trick: To enhance inhaled antibiotic deposition, temporarily increase tidal volume from 6 to 8 mL/kg during nebulization only (15-20 min), then return to lung-protective ventilation.

7. The Rapid Phenotypic Shortcut: Can't wait 48-72 hours for full susceptibility? Use rapid phenotypic tests:

   • Modified carbapenem inactivation method (mCIM): Detects carbapenemase in 6-8 hours
   • MALDI-TOF with Carba-R kit: Results in 15-30 minutes

8. The Source Control Multiplier: Even cefiderocol won't save a patient with undrained empyema or unreplaced infected central line. Antibiotic efficacy = antimicrobial activity × source control adequacy.

Oysters 🦪 (Hidden Dangers)

1. The CAZ-AVI Resistance Trap: Resistance can emerge during therapy for high-burden infections (pneumonia, abscesses). Monitor clinical response closely; if deteriorating after initial improvement at day 4-5, suspect resistance and send repeat cultures.

2. The Cefiderocol MIC Mirage: Standard susceptibility testing OVERESTIMATES resistance. Ensure your lab uses iron-depleted media. An isolate may appear resistant on routine testing but actually susceptible with proper methodology.

3. The Polymyxin-Carbapenem "Antagonism": In vitro studies show apparent antagonism between polymyxins and carbapenems against some CRE isolates. Clinical significance remains unclear, but avoid this combination unless other options exhausted.

4. The Colistin Dose Confusion: Converting between international units (IU), mg of colistimethate sodium (CMS), and mg of colistin base activity (CBA) is treacherous:

   • 1 mg CBA = 30,000 IU = 2.4 mg CMS (approximately)
   • Always clarify which unit your pharmacy uses to avoid 10-fold dosing errors

5. The Aminoglycoside Obesity Paradox: Dosing on total body weight in morbidly obese patients (BMI >40) leads to toxicity. Use adjusted body weight:

   • ABW = IBW + 0.4(TBW - IBW)
   • Where IBW = 50kg (males) or 45.5kg (females) + 2.3kg per inch over 5 feet

6. The Inhaled Antibiotic Bronchospasm: Occurs in 10-20% of recipients, usually within first 2 doses. Pre-medicate all patients with albuterol 15 minutes before aerosolized colistin. Have emergency bronchodilators at bedside.

7. The "Double Colistin" Toxicity: When combining IV colistin with inhaled colistin, systemic absorption of inhaled drug (10-15%) adds to nephrotoxicity risk. Monitor creatinine religiously and consider switching IV polymyxin to polymyxin B while continuing inhaled colistin.

8. The CRRT Clearance Gamble: High-volume CRRT (>35 mL/kg/h) clears some antibiotics unpredictably:

   • Significantly cleared: Carbapenems, cefiderocol, aminoglycosides, colistin prodrug
   • Minimally cleared: Polymyxin B, tigecycline, daptomycin
   • When in doubt, measure levels; don't guess

9. The Aztreonam Allergy Cross-Reactivity Myth: Aztreonam does NOT cross-react with penicillins/cephalosporins in truly IgE-mediated allergies (it's a monobactam). Safe in penicillin-allergic patients. Use liberally for MBL-producers when avibactam combinations unavailable.

10. The Fosfomycin Monotherapy Fiasco: Fosfomycin has activity against many MDR Gram-negatives but resistance emerges rapidly with monotherapy. Never use as monotherapy for serious infections; reserve for combinations or UTI suppression only.

---

Practical Hacks for the Busy Intensivist

Hack #1: The "Resistance Gene to Drug" Quick Reference

Keep this flowchart at your workstation:

Carbapenemase Detected → Choose Drug:

• KPC → CAZ-AVI or meropenem-vaborbactam (first-line)
• NDM/VIM/IMP (MBLs) → Cefiderocol OR aztreonam + CAZ-AVI
• OXA-48 → CAZ-AVI or cefiderocol
• Multiple genes → Cefiderocol + infectious diseases consult

Hack #2: The "Augmented Renal Clearance Detector"

Suspect ARC in patients with:

• Age <50 years + trauma/burns/sepsis
• Measured CrCl >130 mL/min on 24-hour urine collection
• Serum creatinine <0.7 mg/dL despite normal muscle mass

Action: Increase β-lactam doses by 30-50% or shorten intervals. Request TDM if available.

Hack #3: The "Nebulizer Setup Checklist"

Print and laminate for bedside nurses:

• ☐ Remove HME filter
• ☐ Place nebulizer 15-20 cm from Y-piece on inspiratory limb
• ☐ Switch to volume control mode
• ☐ Reduce RR to 10-12/min
• ☐ Suction patient first
• ☐ Give albuterol pre-treatment (if ordered)
• ☐ Silence alarms temporarily
• ☐ Document time started/completed
• ☐ Replace HME after treatment

Hack #4: The "Polymyxin vs Polymyxin Decision Tree"

Patient needs polymyxin therapy
│
├─ On RRT or CrCl <30? 
│  ├─ YES → Polymyxin B (no dose adjustment)
│  └─ NO → Continue
│
├─ TDM available?
│  ├─ YES → Colistin (can target levels)
│  └─ NO → Polymyxin B (simpler)
│
└─ Either acceptable → Polymyxin B (trend favors less nephrotoxicity)

Hack #5: The "Aminoglycoside Redosing Trigger"

For patients on extended-interval aminoglycosides:

• Check trough level 30 min before scheduled next dose
• If trough <1 mg/L (gentamicin/tobramycin): Give next dose on schedule
• If trough 1-2 mg/L: Delay dose 12-24 hours, recheck level
• If trough >2 mg/L: Hold dose, recheck q24h until <1 mg/L

Hack #6: The "72-Hour Reassessment Protocol"

At 72 hours of empiric MDR therapy, mandate reassessment:

1. Culture results back? De-escalate if possible
2. Clinical improvement? Continue current regimen
3. Worsening despite susceptible organism? Check source control; consider TDM; add adjuncts (inhaled antibiotics)
4. Resistance emerged? Switch agents; ID consult; ensure source controlled

Hack #7: The "Emergency Antibiogram"

Create a pocket card with YOUR ICU's resistance patterns (update quarterly):

• K. pneumoniae CAZ-AVI susceptibility: ____%
• P. aeruginosa cefiderocol susceptibility: ____%
• A. baumannii colistin susceptibility: ____%
• Carbapenemase prevalence: KPC ___%, NDM ___%, OXA-48 ___%

Use this to inform empiric choices before cultures return.

---

Future Directions and Emerging Therapies

On the Immediate Horizon (2025-2027)

1. Aztreonam-Avibactam: Likely FDA approval in 2025 for complicated intra-abdominal and urinary infections. Will become preferred agent for MBL-producing CRE, potentially replacing cefiderocol.

2. Zidebactam-Cefepime: Novel β-lactam enhancer with direct activity against A. baumannii. Phase 3 trials completed; may offer first reliable β-lactam option for carbapenem-resistant Acinetobacter.

3. Murepavadin: First-in-class outer membrane protein-targeting antibiotic specific for P. aeruginosa. Development paused due to nephrotoxicity, but reformulation ongoing.

Disruptive Technologies

Phage Therapy: Engineered bacteriophages showing promise for compassionate-use cases of XDR infections. Centers of excellence emerging (UCSD, Yale). Consider for patients failing all conventional therapy with isolated, characterized organism.

Antibiotic-Loaded Nanoparticles: Enhance lung penetration and reduce systemic toxicity. In preclinical development for aerosolized colistin and amikacin formulations.

Immunomodulatory Adjuncts: Combinations of antibiotics with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interferon-gamma showing synergy in animal models of carbapenem-resistant pneumonia.

Precision Medicine Approaches

Pharmacogenomics: CYP450 polymorphisms affecting aminoglycoside clearance identified. Future: genotype-guided dosing to minimize toxicity.

Real-Time TDM: Point-of-care devices for rapid measurement of β-lactam and aminoglycoside levels (results in <30 minutes vs. 24-48 hours for send-out assays). Currently in pilot testing at academic centers.

Machine Learning Algorithms: AI-powered antibiograms predicting resistance patterns based on patient risk factors, prior cultures, and local epidemiology. Early studies show 15-20% improvement in appropriate empiric therapy selection.

---

Take-Home Messages

The intensivist managing MDR Gram-negative infections in 2025 must be simultaneously:

• A microbiologist (understanding resistance mechanisms)
• A pharmacologist (optimizing PK/PD in physiologic chaos)
• A proceduralist (prioritizing source control)
• An evidence synthesizer (interpreting imperfect trial data)

Success requires moving beyond "what antibiotic should I use?" to "how do I maximize the probability this specific antibiotic works in this specific patient?"

The tools exist—novel agents with remarkable activity, pharmacokinetic principles to optimize dosing, adjunctive strategies to enhance delivery. But tools without skill remain ineffective. Master the fundamentals: obtain appropriate cultures before antibiotics when possible, involve infectious diseases and clinical pharmacology early, measure levels when available, and always—always—ensure source control.

In an era of increasing resistance and dwindling options, therapeutic success lies not in waiting for the next miracle drug, but in perfecting the use of what we already have.

---

Acknowledgments

The author thanks the countless ICU nurses, pharmacists, and respiratory therapists whose meticulous attention to technical details—proper nebulizer setup, precise timing of aminoglycoside levels, vigilant monitoring for nephrotoxicity—transforms theoretical pharmacology into saved lives.

---

Word Count: 2,983

Disclosure: The author has no financial conflicts of interest to disclose. No pharmaceutical company funding supported this work.

---

For correspondence and questions regarding implementation of these strategies, consult your institutional antimicrobial stewardship program and infectious diseases service. Local resistance patterns and formulary availability should guide final therapeutic decisions.